tanshen
also
known
salvia
miltiorrhiza
red
sage
chines
sage
danshen
wide
use
tradit
chines
medicin
treatment
cerebrovascular
cardiovascular
diseas
well
inflammatori
tanshinon
major
liposolubl
constitu
tanshen
consist
abietan
typediterpen
quinon
primari
bioactiv
constitu
among
tanshinon
tanshinon
tni
tanshinon
iia
tniia
cryptotanshinon
cpt
figur
attract
special
attent
possess
variou
pharmacolog
effect
includ
antiinflammatori
anticanc
cardiocerebrovascular
protect
tniia
studi
potenti
effect
diabet
neurodegen
diseas
cardiac
addit
antiinflammatori
anticanc
effect
tni
also
enhanc
abil
memor
learn
amelior
memori
recent
number
studi
publish
concern
modif
biosynthesi
metabol
pharmacolog
action
therapeut
applic
howev
poor
water
solubl
low
oral
bioavail
tanshinon
limit
clinic
applic
review
focus
drug
deliveri
system
tanshinon
date
give
summari
current
research
progress
tanshinon
organ
review
describ
later
first
review
outlin
variou
pharmacolog
tanshinon
figur
indic
high
medicin
valu
develop
drug
deliveri
system
tanshinon
discuss
includ
liposom
solid
dispers
nanoparticl
np
use
solv
poor
bioavail
tanshinon
final
make
conclus
person
perspect
direct
develop
tanshinon
tanshinon
investig
treatment
cardiocerebrovascular
diseas
myocardi
infarct
atherosclerosi
hyperlipidemia
hypertens
tniia
deriv
sodium
tniia
sulfon
st
found
significantli
reduc
size
myocardi
infarct
improv
cardiac
function
via
activ
phosphatidylinositol
kinas
protein
kinas
b
akt
signal
pathway
tniia
also
inhibit
format
atherosclerot
lesion
hyperlipidemia
reduc
oxid
lowdens
lipoprotein
cholesterol
accumul
macrophag
platelet
aggreg
monocyt
adhes
addit
tniia
st
attenu
pulmonari
hypertens
modul
calcium
potassium
channel
inhibit
prolifer
migrat
vascular
smooth
muscl
cell
block
akt
tniia
tni
protect
brain
ischem
damag
stroke
model
reduc
brain
infarct
volum
restor
neurolog
function
might
correl
induc
nuclear
transloc
transduc
regul
camp
respons
elementbind
protein
creb
upregul
express
phosphoryl
pcreb
brainderiv
neurotroph
clinic
studi
unstabl
angina
pectori
uap
patient
mg
st
combin
mg
aspirin
significantli
attenu
angina
pectori
clinic
trial
miltiorrhiza
tanshinon
patient
ischem
condit
well
summar
recent
anticanc
activ
tanshinon
systemat
summar
inform
tniia
tni
cpt
potent
cytotox
agent
significantli
inhibit
growth
surviv
multipl
type
cancer
cell
induc
cell
cycl
arrest
apoptosi
micromolar
level
potenti
mechan
involv
includ
upregul
proapoptosi
protein
bax
etc
downregul
antiapoptosi
protein
includ
survivin
cmyc
activ
caspas
protein
trigger
cell
tniia
also
found
induc
autophag
cell
death
variou
cancer
cell
activ
ampactiv
protein
kinas
extracellular
signalregul
kinas
erk
inhibit
mammalian
target
rapamycin
kda
ribosom
protein
kinas
signal
addit
tniia
tni
abl
inhibit
migrat
invas
metastasi
cancer
cell
alter
matrix
metalloproteinas
andor
tissu
inhibitor
notabl
tniia
also
promot
cell
differenti
sever
cancer
cell
type
like
regul
ccaatenhanc
bind
protein
cebp
beta
cebp
homolog
protein
furthermor
tniia
tni
cpt
exhibit
promis
anticanc
effect
minor
side
effect
mani
xenograft
anim
tniia
tni
cpt
synergist
anticanc
effect
chemotherapeut
drug
cisplatin
doxorubicin
arsen
moreov
tniia
tni
cpt
overcom
pglycoprotein
pgp
mediat
multidrug
resist
cancer
act
substrat
pgp
suppress
pump
clinic
use
tiia
cancer
treatment
report
patient
acut
promyelocyt
leukemia
respons
alltran
retino
acid
atra
mg
three
time
per
day
day
achiev
complet
remiss
treat
tiia
mg
oral
two
time
per
day
cancerrel
clinic
trial
tiia
tanshinonecontain
tradit
chines
medicin
formula
well
present
tniia
shown
remark
antiinflammatori
activ
inhibit
express
inflammatori
mediat
includ
interleukin
il
beta
tumor
necrosi
factor
tnf
alpha
estrogen
receptor
subtypedepend
manner
murin
macrophag
cell
pretreat
lipopolysaccharid
lp
addit
tniia
suppress
lpsinduc
nuclear
factor
kappab
activ
inhibit
kinaseikappab
alpha
kinas
nikikkalpha
cjun
ntermin
kinas
jnk
recent
data
protein
interact
network
analysi
suggest
antiinflammatori
effect
tniia
may
result
part
activ
tnf
receptorassoci
factor
traf
inhibit
tolllik
receptor
tlr
signal
tni
significantli
inhibit
activ
group
iia
secretori
phospholipas
giia
therebi
block
prostaglandin
format
lpsactiv
macrophag
exhibit
vivo
antiinflammatori
activ
rat
adjuvantinduc
arthriti
carrageenaninduc
paw
tni
cpt
also
significantli
inhibit
product
lpsactiv
macrophag
product
lymph
node
tanshinon
known
natur
antioxid
form
quinon
adduct
lipid
radic
form
stabil
tniia
abl
prevent
dna
damag
liver
cell
result
lipid
peroxid
scaveng
lipid
free
radic
break
peroxid
chain
preincub
tniia
significantli
decreas
death
human
umbil
vein
endotheli
cell
addit
tni
activ
factor
depend
antioxid
respons
prevent
ubiquitinationmedi
degrad
protect
iii
induc
lung
damag
vitro
tni
inhibit
peroxynitriteinduc
dna
damag
diminish
noxidehydroxyl
dmpooh
radic
adduct
signal
tanshinon
also
potent
antiosteoporot
activ
target
differ
pathway
bone
remodel
demonstr
tniia
tni
cpt
obviou
inhibitori
effect
osteoclast
found
experi
tniia
inhibit
osteoclast
differenti
block
akt
erk
activ
downregul
express
cfo
nuclear
factor
activ
tcell
cytoplasm
calcineurindepend
induc
receptor
activ
furthermor
tniia
also
suppress
bone
resorpt
differenti
notabl
tniia
tni
insulinsensit
effect
enhanc
abil
insulin
promot
tyrosin
phosphoryl
insulin
receptor
activ
downstream
erk
akt
glycogen
synthas
beta
kinas
chines
hamster
ovari
cell
shown
cpt
potent
antibacteri
activ
wide
rang
gramposit
bacteria
reactiv
oxygen
speci
ro
depend
potenti
treat
alzheim
diseas
inhibitor
particularli
major
tanshinon
tniia
tni
cpt
abl
competit
inhibit
metabol
tniia
cpt
efficaci
pregnan
x
receptor
pxr
agonist
induc
express
suggest
attent
paid
tanshinon
use
combin
drug
metabol
recent
tniia
tni
cpt
found
specif
select
inhibitor
sarscov
cystein
proteas
plpro
exert
signific
inhibitori
effect
proteas
includ
chymotrypsin
papain
hiv
moreov
tniia
could
inhibit
tatinduc
transactiv
redoxregul
ampknampt
liposom
close
spheric
vesicl
compos
lipid
bilay
attract
properti
includ
biocompat
biodegrad
low
clearanc
rate
low
establish
highli
effici
deliveri
system
multipl
function
one
therapeut
drug
entrap
within
aqueou
liposom
interior
embed
liposom
membran
depend
characterist
drug
process
benefit
liposom
use
encapsul
glycyrrhetin
acid
ga
salvianol
acid
b
sb
tniia
enhanc
bioavail
water
solubl
compound
exert
synergist
effect
inhibit
hepat
stellat
cell
hsc
studi
tsiia
ga
hydrophob
constitu
incorpor
phospholipid
bilay
employ
film
hydrat
method
probe
sonic
phgradient
method
use
load
hydrophil
constitu
sb
final
yield
gatniiasb
compound
liposom
gtslip
cholesterol
soybean
phospholipid
eventu
encapsul
effici
drug
littl
differ
among
individu
compound
studi
demonstr
gtslip
could
suppress
prolifer
hsc
sustainedreleas
effect
effect
mix
solut
ga
tniia
sb
may
promot
clinic
applic
therapeut
activ
outstand
advantag
liposom
drug
deliveri
system
abil
coencapsul
differ
drug
exert
synergist
effect
sustainedreleas
manner
effici
treatment
unencapsul
drug
howev
challeng
still
exist
control
ratio
differ
drug
produc
improv
heal
efficaci
emuls
class
formul
consist
two
immisc
phase
stabil
wide
use
enhanc
stabil
activ
constitu
therebi
maintain
previou
studi
lipid
soybean
phospholipid
pluron
glycerol
oleic
acid
lecithin
use
produc
tniia
formul
longterm
stabil
obviou
anticanc
activ
howev
nanoemuls
prove
higher
bioaccess
stabil
optic
clariti
convent
emuls
nanoemuls
similar
microemuls
monodispers
spheric
droplet
thermodynam
stabil
well
excel
solubl
recent
year
seri
studi
report
regard
prepar
process
qualiti
control
evalu
profil
tanshinon
tniia
encapsul
microemuls
consist
phospholipid
ethyl
oleat
glycerol
antitumor
effect
hepatoma
cell
moreov
anoth
tniia
microemuls
mean
droplet
size
nm
prepar
improv
bioavail
rat
small
intestin
result
absorpt
small
intestin
tniia
microemuls
show
tniia
microemuls
could
improv
absorpt
tniia
rat
small
intestin
influenc
waterphas
ratio
tniia
microemuls
absorpt
addit
tniia
nanoemuls
form
averag
particl
size
nm
excel
entrap
effici
show
potent
cytotox
greater
tniia
alon
human
bladder
cancer
cell
time
dosedepend
also
report
tanshinon
microemuls
possess
cytotox
effect
human
leukemia
cell
line
method
establish
high
perform
liquid
chromatographi
fingerprint
tanshinon
microemuls
develop
control
although
tniia
emuls
excel
longterm
stabil
anticanc
activ
conveni
enough
prepar
emuls
four
type
materi
may
hinder
applic
tniia
emuls
unsatisfactori
bioavail
cd
deriv
includ
cagelik
supramolecular
structur
abil
form
inclus
complex
variou
molecul
complex
use
drug
carrier
number
applic
nasal
administr
oral
drug
deliveri
dermal
drug
deliveri
enhanc
stabil
solubl
bioavail
henc
inclus
complex
tniia
tni
cd
obtain
via
coprecipit
lyophil
enhanc
level
biolog
util
result
prove
greater
stabil
furthermor
transport
mechan
found
recircul
intestin
perfus
passiv
transport
particular
absorpt
site
tniia
vivo
permeabl
rate
intestin
epitheli
membran
seven
time
higher
free
tniia
indic
complex
enhanc
gastrointestin
tract
absorpt
addit
inclus
complex
cpt
inclus
ratio
prepar
wet
grind
method
significantli
improv
dissolut
product
solid
dispers
techniqu
improv
dissolut
rate
bioavail
poorli
watersolubl
drug
dispers
drug
solidst
hydrophil
carrier
increas
surfac
therefor
solid
dispers
tniia
tni
cpt
appli
improv
dissolut
stabil
bioavail
tanshinon
variou
type
carrier
use
prepar
solid
dispers
tniia
via
solvent
techniqu
spraydri
method
combin
polyvinylpyrrolidon
pvp
nanosilica
poloxam
povidon
porou
copovidon
low
molecular
weight
chitosan
lmc
among
best
dissolut
rate
tniia
solid
dispers
addit
better
dissolut
rate
tniiasilica
np
moreov
proport
improv
solubl
minut
could
store
month
chang
dissolut
compon
littl
moistur
absorpt
better
moreov
lmc
tniia
weight
ratio
use
prepar
solid
dispers
increas
dissolut
rate
compar
free
tniia
could
enhanc
absorpt
rate
oral
also
report
ternari
solid
dispers
compos
tniia
demonstr
high
dissolut
rate
stabil
repres
promis
method
prepar
solid
despit
benefit
solid
dispers
mention
earlier
necessari
obtain
longliv
circul
within
human
bodi
greater
efficaci
cancer
np
loos
defin
particl
nm
enhanc
solubl
dissolut
rate
drug
decreas
particl
size
enlarg
surfac
therefor
number
polymer
carrier
use
prepar
np
tniia
better
bioavail
poli
llacticcoglycol
acid
plga
polylact
acid
pla
cation
bovin
serum
albumin
cbsa
conjug
pegyl
np
tniiaload
plga
tniiaplganp
good
biocompat
high
absorpt
prevent
effect
neointim
hyperplasia
rabbit
carotid
arteri
intim
furthermor
effici
prepar
tniiaplganp
nanoprecipit
method
instead
emuls
evapor
method
result
particl
averag
diamet
nm
entrap
effici
drug
load
drug
recoveri
rate
anoth
type
materi
pla
use
prepar
novel
np
tniia
tniiaplanp
singl
oilinwat
emulsionsolv
evapor
method
result
particl
signific
dose
timedepend
growthinhibitori
effect
hepatoma
sustain
releas
vitro
vivo
surviv
time
mice
bear
hepatoma
tumor
despit
enhanc
bioavail
water
solubl
tniia
np
mention
earlier
effici
modifi
np
obtain
extend
circul
within
human
bodi
result
tniia
np
modifi
peg
polyethylen
glycol
enabl
extend
circul
within
human
bodi
potent
pharmacolog
activ
tniia
pegyl
nanoparticl
pegtniianp
prepar
use
doubl
emulsionsolv
evapor
techniqu
conjug
cbsa
maleimid
function
final
form
cbsapegtniianp
long
circul
time
hour
better
uptak
effici
brain
tniia
solut
studi
also
indic
cbsapegtniianp
exhibit
signific
neuroprotect
effect
ischem
stroke
could
suppress
microgli
activ
inhibit
neutrophil
infiltr
downregul
multipl
proinflammatori
cytokin
via
regul
mapk
ppar
signal
moreov
solid
lipid
np
cpt
prepar
ultrason
highpressur
homogen
method
improv
low
bioavail
soy
lecithin
tween
although
tniia
np
greater
bioavail
well
water
solubl
long
circul
time
human
bodi
excel
pharmacolog
effect
would
promis
prepar
polymer
np
tniia
capabl
target
deliveri
attract
much
attent
due
enhanc
cell
uptak
drug
minim
system
side
addit
formul
tniia
mention
earlier
also
use
enhanc
solubl
stabil
tniia
sever
materi
appli
tniia
pellet
sustain
releas
includ
hydroxypropyl
methylcellulos
hpmc
pvp
polyvinyl
acet
pvac
poli
vinyl
alcohol
poli
ethylen
glycol
pvapeg
graft
addit
dalphatocopheryl
polyethylen
glycol
succinategraftplga
tpgsgplga
copolym
use
form
mix
micel
improv
bioavail
prolong
circul
time
hepatocellular
howev
neither
formul
target
deliveri
system
improv
cellular
uptak
tniia
overcom
low
bioavail
tanshinon
mani
method
use
improv
solubl
dissolut
rate
well
prolong
circul
time
compound
particular
solid
dispers
np
shown
better
result
formul
recent
research
formul
tissu
specif
enhanc
pharmacolog
effect
tniia
necessari
design
type
drug
prepar
compon
activ
target
tumor
tissu
part
bodi
despit
high
dissolut
rate
tanshinon
obtain
novel
techniqu
littl
develop
clinic
applic
formul
due
complex
process
produc
formul
lack
research
tniia
formul
clinic
trial
ultim
goal
pharmaceut
research
addit
necessari
clarifi
light
sensit
tniia
futur
research
develop
tniia
prepar
may
part
driven
lack
inform
conclus
expect
effort
develop
drug
deliveri
system
tanshinon
clinic
applic
formul
tanshinon
make
breakthrough
better
therapi
futur
